Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Spillane

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
The Cochrane Database of Systematic Reviews|August 22, 2025
FcRn inhibitors for myasthenia gravisLaura M White, Fiona J Clay, Anne-Marie Forbes, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 10, 2022
IVIg-exposure and thromboembolic event risk: findings from the UK BiobankMahima Kapoor, Ian Hunt, Jennifer Spillane, et al.
Practical Neurology|September 12, 2025
Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)Saiju Jacob, Maria Elena Farrugia, Channa Hewamadduma, et al.
Neuromuscular Disorders : NMD|April 16, 2024
Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravisKatherine C Dodd, Rohan Ahmed, Philip Ambrose, et al.
BMJ Neurology Open|June 3, 2021
Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosisKushan Karunaratne, Dariush Ahrabian, Bernadette Monoghan, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 14, 2024
Pharmacogenetic and microRNA mechanisms of beta blocker use on boneChristine W Lary, Elizabeth J Atkinson, Jennifer Spillane, et al.
Med (New York, N.Y.)|February 7, 2026
Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravisKatherine C Dodd, Kirsten Baillie, James K L Holt, et al.
Neurology|October 4, 2022
Neuromuscular Features in XL-MTM Carriers: A Cross-sectional Study in an Unselected CohortDaniëlle K Franken, Karlijn Bouman, Stacha F I Reumers, et al.
Emerging Infectious Diseases|November 20, 2019
Rhombencephalitis and Myeloradiculitis Caused by a European Subtype of Tick-Borne Encephalitis VirusLorna Neill, Anna M Checkley, Laura A Benjamin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 11, 2025
Efgartigimod efficacy and safety in refractory myasthenia gravis: UK's first real-world experienceJoana Moniz Dionísio, Philip Ambrose, Georgina Burke, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
The Cochrane Database of Systematic Reviews|August 22, 2025
FcRn inhibitors for myasthenia gravisLaura M White, Fiona J Clay, Anne-Marie Forbes, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 10, 2022
IVIg-exposure and thromboembolic event risk: findings from the UK BiobankMahima Kapoor, Ian Hunt, Jennifer Spillane, et al.
Practical Neurology|September 12, 2025
Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)Saiju Jacob, Maria Elena Farrugia, Channa Hewamadduma, et al.
Neuromuscular Disorders : NMD|April 16, 2024
Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravisKatherine C Dodd, Rohan Ahmed, Philip Ambrose, et al.
BMJ Neurology Open|June 3, 2021
Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosisKushan Karunaratne, Dariush Ahrabian, Bernadette Monoghan, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 14, 2024
Pharmacogenetic and microRNA mechanisms of beta blocker use on boneChristine W Lary, Elizabeth J Atkinson, Jennifer Spillane, et al.
Med (New York, N.Y.)|February 7, 2026
Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravisKatherine C Dodd, Kirsten Baillie, James K L Holt, et al.
Neurology|October 4, 2022
Neuromuscular Features in XL-MTM Carriers: A Cross-sectional Study in an Unselected CohortDaniëlle K Franken, Karlijn Bouman, Stacha F I Reumers, et al.
Emerging Infectious Diseases|November 20, 2019
Rhombencephalitis and Myeloradiculitis Caused by a European Subtype of Tick-Borne Encephalitis VirusLorna Neill, Anna M Checkley, Laura A Benjamin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 11, 2025
Efgartigimod efficacy and safety in refractory myasthenia gravis: UK's first real-world experienceJoana Moniz Dionísio, Philip Ambrose, Georgina Burke, et al.
Pageof 4